Shots:

• Eidos to receive $25M upfront- $25 equity investment at a premium to the market price upon deal execution- milestone and royalties. Alexion to get an exclusive license to develop & commercialize AG10 in Japan
• The focus of the agreement is to expand Alexion’s amyloidosis portfolio with the addition of Eidos’ AG10 for patients with transthyretin amyloidosis (ATTR)
• AG10 (PO) is an investigational therapy to stabilize tetrameric transthyretin- currently being evaluated in P-III study in the US and EU for ATTR cardiomyopathy and demonstrated 90% TTR stabilization @28days in its P-II study. Eidos plans to initiate P-III study of AG10 for ATTR polyneuropathy

Click here to­ read full press release/ article | Ref: Alexion | Image: Twipu